In this TCT 2021 episode of Parallax, Dr Ankur Kalra’s guest is Prof Mamas Mamas, Consultant Interventional Cardiologist at University Hospitals of North Midlands NHS Trust (UHNM), Professor of Cardiology at Keele University and Senior Clinical Editor of TCTmd.
Ankur invites Mamas to talk about the clinical relevance of some of the top studies presented at TCT 2021. Mamas summarises the studies, some of their salient features and the findings. Ankur and Mamas discuss the strategies they currently apply in their US and UK based practices and share how they think the novel data will guide their decision-making.
What are the questions that emerged from the new data? What are the controversies? How do these trials challenge our current practice?
Trials covered in detail include:
FAME 3: A Randomized Trial of FFR-Guided Stenting Compared With CABG
EROSION III: A Randomized Trial of OCT-Guided Intervention in STEMI Patients With Early Infarct Artery Patency
OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG
Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode. Guest @mmamas1973 hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Brought to you by Edwards: www.edwardstavr.com
Together, Dr Kalra and Dr Darlington delve into the significance of assessing volume status in patients with heart failure, highlighting its continued relevance in 2024, including the availability of new diagnostic tools, including the Heart Failure Management System (HFMS).
This series is supported by ZOLL and is intended for Health Care Professionals.
This series is supported by ZOLL and is intended for Health Care Professionals.